A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Inclusion Criteria: * An acute-care inpatient encounter with a principal or secondarydiagnosis of VTE, or an ambulatory-care encounter with any diagnosis of VTE * An outpatient pharmacy claim for apixaban or warfarin during the 30-day period following the index encounter * Continuous and comprehensive medical/drug coverage for ≥6 months preceding the index encounter Exclusion Criteria: * Evidence of a trial fibrillation/flutter or chemotherapy/radiation therapy for malignancy (other than non-melanoma skin cancer) during 6-month period preceding first receipt of index therapy * Evidence of VTE(VTE event)during 6-month period preceding index encounter * Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period preceding first receipt of index therapy Other protocol defined inclusion/exclusion criteria could apply